Core Insights - Codexis, Inc. and Nitto Denko Avecia, Inc. have entered into an evaluation agreement to explore Codexis' ECO Synthesis® Manufacturing Platform, which aims to enhance oligonucleotide therapeutics manufacturing [1][2][3] Company Overview - Codexis is a leader in enzymatic solutions for therapeutic manufacturing, focusing on high-quality and efficient production methods that surpass traditional techniques [4] - Nitto Denko Avecia specializes in contract development and manufacturing of oligonucleotide therapeutics, with a strong portfolio and extensive experience in the field [4] Collaboration Details - The agreement will facilitate licensing discussions and promote broader adoption of the ECO Synthesis platform, which utilizes an enzyme-catalyzed approach for scalable manufacturing [2][3] - This partnership is seen as a significant milestone for both companies, aiming to redefine scalability and sustainability in therapeutic development [3] Strategic Goals - The collaboration aligns with Nitto Denko Avecia's mission to innovate in oligonucleotide manufacturing and deliver high-quality therapeutics globally [3] - Codexis aims to expand the reach of its ECO Synthesis platform through strategic partnerships with leading CDMOs [3]